{
  "docId": "019de071-67f9-727e-bc6c-51745a3c53ca",
  "docSlug": "89984315105a6609dc5e897dea039740",
  "documentTitle": "Ginkgo | Results Presentation Deck | 30 slides",
  "authorId": "ginkgo",
  "authorName": "Ginkgo Bioworks",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 30,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "customer_journey",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Includes a CEO quote from Cronos Q2 2021 earnings call.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-67f9-727e-bc6c-51745a3c53ca/17",
  "deckHref": "/decks/019de071-67f9-727e-bc6c-51745a3c53ca",
  "deckJsonHref": "/decks/019de071-67f9-727e-bc6c-51745a3c53ca.json",
  "deckAnchorHref": "/decks/019de071-67f9-727e-bc6c-51745a3c53ca#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "diagram",
      "text": "Cannabinoid production pathway from precursors to decarboxylation",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1925d0d-12c9-4176-8666-0694d477f229",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.03,
        "y": 0.345
      },
      "kind": "list",
      "text": "Ginkgo Bioworks to design microorganisms which can produce desired “target cannabinoids” at an industrial scale; 8 target cannabinoids to be produced by yeast via industrial fermentation; Target production yields at a fraction of the cost of traditional cannabinoids production in plants: < $1,000 USD per KG; Cronos Group will have the exclusive right to use and commercialize the key patented intellectual property related to the production of the target cannabinoids perpetually and globally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ead1985c-5e31-4dd5-bb99-d044a3dc4a14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.43,
        "x": 0.53,
        "y": 0.28
      },
      "kind": "quote",
      "text": "At this stage, we have all the necessary licenses to commercialize a product using cultured cannabinoids produced in our Winnipeg facility... We'll be using cultured CBG as our first product introduced to the market...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64541dcb-9f66-4b59-a112-8cb0a3d993e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.03,
        "y": 0.945
      },
      "kind": "source-note",
      "text": "Source: Cronos Group (FINAL Ginkgo Deal Announcement Presentation, September 4, 2018)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50452f44-a4d9-4490-9302-89f4874ae810",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.43,
        "x": 0.53,
        "y": 0.68
      },
      "kind": "table",
      "text": "Collaboration in Brief: Partner (signed 2018), Program Goals, Progress to Date",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c86c05a4-6fa2-4135-bd3d-345af96ce6ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.75,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Ginkgo is developing 8 molecules for Cronos through two major programs, the first of which is expected to be commercialized this year",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "695ef750-6cb5-4c7a-9ca5-989f88c14499",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 15,
      "beatId": "e62a2e67-7e9c-4302-b9f0-5a4bd8c0f53a",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "The Breakthrough",
      "beatSlug": "rags-to-riches-the-breakthrough",
      "evidence": "The document showcases Ginkgo Bioworks' partnerships and collaborations, driving growth and innovation.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}